Tiziana Life Sciences not to engage in capital raising activities for the immediate future
Provided By GlobeNewswire
Last update: Jan 23, 2025
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces its intention not to engage in a capital raising activities for the immediate future.
Read more at globenewswire.com
